Insulin is uniting 2020’s bickering presidential hopefuls
The Democrats running for president have squabbled over Medicare for All, international pricing indices, and the cost of drug research. But they all agree on one thing: The cost of insulin is too damn high.
As STAT’s Lev Facher reports from Iowa, the rising price of the life-saving treatment has united the likes of Amy Klobuchar and Bernie Sanders, each of whom has lambasted pharma for perceived profiteering, with insulin as an example.
That’s perhaps because the nuances of the American drug supply chain don’t fit neatly into a stump speech, while pointing to insulin, among the most commonly used medicines in the country, is simple. The issue is also an easy cudgel against President Trump: Eli Lilly, the original U.S. insulin manufacturer, is the former employer of health secretary Alex Azar.
Read more.
As STAT’s Lev Facher reports from Iowa, the rising price of the life-saving treatment has united the likes of Amy Klobuchar and Bernie Sanders, each of whom has lambasted pharma for perceived profiteering, with insulin as an example.
That’s perhaps because the nuances of the American drug supply chain don’t fit neatly into a stump speech, while pointing to insulin, among the most commonly used medicines in the country, is simple. The issue is also an easy cudgel against President Trump: Eli Lilly, the original U.S. insulin manufacturer, is the former employer of health secretary Alex Azar.
Read more.
No hay comentarios:
Publicar un comentario